Navigation Links
Contact lens discomfort: What is it, why does it occur and how can it be treated?
Date:10/21/2013

BOSTON, MA, October 21, 2013 Contact lens discomfort (CLD) may be the leading cause of patient dissatisfaction with, and discontinuation of, contact lens wear throughout the world but there is little agreement among vision researchers and eye care professionals about how to define and manage its causes.

"Up to half of all contact lens wearers experience CLD," explained Jason J. Nichols, OD, MPH, PhD, Professor at the University of Houston College of Optometry. "However, there is no global consensus concerning the definition, classification, epidemiology, pathophysiology, diagnosis, management and the proper design of clinical studies for CLD."

To lay the groundwork for defining and treating this widespread issue, the Tear Film & Ocular Surface Society (TFOS; http://www.tearfilm.org) organized the TFOS International Workshop on Contact Lens Discomfort (CLD), which was chaired by Nichols. The findings were reported Friday in the current issue of journal Investigative Ophthalmology & Visual Science.

The CLD Workshop took 18 months to complete and involved 79 experts from around the world. "Workshop participants used an evidence-based approach and a process of open communication, dialogue, and transparency in order to achieve a global consensus concerning multiple aspects of CLD," noted Mark Willcox, PhD, FBCLA, FAAO, MASM, Professor, School of Optometry & Vision Science, University of New South Wales, and Vice-Chair of the Workshop.

"This TFOS report will significantly increase awareness of factors that may, and may not, contribute to the generation of CLD. Ideally, this TFOS report will stimulate innovative research in this very important field," commented David A. Sullivan, MS, PhD, FARVO,

Founder and recent past TFOS President, Senior Scientist, Schepens Eye Research Institute/Harvard Medical School a
'/>"/>

Contact: Amy Gallant Sullivan
Amy@TearFilm.org
617-605-7128
Association for Research in Vision and Ophthalmology
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Corporate Whistleblower Center Urges Whistleblowers With Proof of Clinical Trial Fraud Involving Tax Dollars to Contact Them About Reward Programs
2. Corporate Whistleblower Center Urges Pharmaceutical Insiders With Proof of Company's Involvement in Adulterated Drugs to Contact Them About Reward Program Information
3. InventHelp® Client Designs a More Ergonomic and Sanitary Way to Handle Contact Lenses (HSC-114)
4. Online Eyeglasses and Contact Lens Sales in the US Industry Market Research Report Now Available from IBISWorld
5. HealthLine Systems' Celebrates 27 Years of Innovation for Healthcare Contact Centers
6. QmedRx Calls for Military Families to Contact Representatives, Demand Compound Drug Coverage
7. Indosoft Improves Q-Suite Real-time ACD Reporting to Enhance Contact Center Productivity
8. United Medical Credit Hires More Staff to Contact Doctors and Promote their Financing Services
9. US Drug Watchdog Now Urges Transvaginal Mesh Failure Victims With Erosion To Call Them For The Names And Contacts Of The Best Women Attorneys
10. Atlanta LASIK Practice Publishes a Patient’s Testimonial About Allergy to Contact Lenses
11. US Drug Watchdog Now Urges Severely Injured Victims Of A Transvaginal Mesh Failure To Call Them for the Contacts Top Women Lawyers-Nationwide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... September 22, 2014 The Spa Standard, ... to lead the start-up in developing content and courses ... to the company over 15 years of experience in ... resort spa management with companies including Orient Express Hotels ... the role of educator, Jenny gained extensive industry insight ...
(Date:9/22/2014)... the proverbial needle in the cancer antigen haystack, according ... of Experimental Medicine . , As cancer ... creates new versions of proteins, some of which are ... cells, prompting the cells to attack and eliminate the ... of the mutations in a patient,s cancer and to ...
(Date:9/22/2014)... 2014--Women who are about to be released from prison ... if they are to successfully reintegrate into their communities ... study. , Almost half of all female prisoners are ... and most have multiple prison terms, mainly for drug-related ... Michael,s Hospital, conducted one-on-one interviews with women who were ...
(Date:9/22/2014)... BCC Research ( http://www.bccresearch.com ) reveals ... GLOBAL MARKETS, the global market for autoimmune disease ... billion by 2019, with a five-year compound annual ... holds the highest market potential due to an ... western lifestyles. , In recent decades, autoimmune ...
(Date:9/22/2014)... on Trauma, patients with severe injuries should be treated ... centers have the resources to provide the best care ... major trauma patients in 2010 actually received their treatment ... a new study from the Center for Pediatric Trauma ... at Nationwide Children,s Hospital. Those patients are "undertriaged." The ...
Breaking Medicine News(10 mins):Health News:The Spa Standard Appoints Vice-President of Content and Course Development 2Health News:Involving female offenders in release planning can increase reintegration success 2Health News:Global Market for Autoimmune Disease Diagnostics to Reach Nearly $13.1 Billion in 2019; Southern Asia Holds the Highest Potential 2Health News:Global Market for Autoimmune Disease Diagnostics to Reach Nearly $13.1 Billion in 2019; Southern Asia Holds the Highest Potential 3Health News:New study finds 34 percent of severely injured patients undertriaged in the United States 2Health News:New study finds 34 percent of severely injured patients undertriaged in the United States 3
... Health plans today proposed guaranteed coverage for people with pre-existing ... , , Under the ... market would be required to offer coverage to all applicants ... individuals were required to maintain health insurance. , ...
... Inc. (NYSE: PRX ) today announced that it ... the U.S. to market budesonide,inhalation suspension, which is a generic ... asthma. Par began,shipping 0.25 mg/2 ml and 0.5 mg/2 ... Full-year US sales for PULMICORT(R) in 2007 totalled ...
... human trial , , WEDNESDAY, Nov. 19 (HealthDay News) -- ... patients may not slow the disease, new research suggests. ... spurred by promising animal research that had suggested that ... on the brain. , However, "the study suggests that ...
... , TORONTO, Nov. 19 /PRNewswire-FirstCall/ - Bradmer ... and commercialization of cancer therapies, announced today that it ... data from Neuradiab(TM) at the Society for Neuro-Oncology,s (SNO) ... from two previously conducted Phase II trials, is titled ...
... medicine community: "Are Your Cells Free?" Learn more about InVitria at TERMIS ... ... Collins, CO (PRWEB) November 19, 2008 -- Stem cell culture researchers ... Tissue Engineering Meeting TERMIS in San Diego on Dec. 7-10. ...
... anniversary of the adoption of the United Nations Convention on the ... ARLINGTON, Va., Nov. 19 The Child Welfare League of America ... Rights of the Child (CRC), the American Psychological Association, and the ... Children,s Health Issues and The Convention on the Rights of the ...
Cached Medicine News:Health News:Health Plans Propose Guaranteed Coverage for Pre-Existing Conditions and Individual Coverage Mandate 2Health News:Health Plans Propose Guaranteed Coverage for Pre-Existing Conditions and Individual Coverage Mandate 3Health News:Par Pharmaceutical Begins Shipment of Budesonide Inhalation Suspension Immediately 2Health News:Growth Hormone Boost May Not Slow Alzheimer's 2Health News:Growth Hormone Boost May Not Slow Alzheimer's 3Health News:Bradmer to present poster on progression free survival and overall survival data from Neuradiab(TM) Phase II trials at Society for Neuro-Oncology Meeting 2Health News:Bradmer to present poster on progression free survival and overall survival data from Neuradiab(TM) Phase II trials at Society for Neuro-Oncology Meeting 3Health News:Bradmer to present poster on progression free survival and overall survival data from Neuradiab(TM) Phase II trials at Society for Neuro-Oncology Meeting 4Health News:InVitria to Launch "BE FREE" Promotion at TERMIS '08 in San Diego 2Health News:Linda Spears, CWLA Vice President of Policy Will Speak at Senate Briefing 2
(Date:9/22/2014)... DALLAS and NEW YORK ... PHARMACEUTICALS, INC. (OTCBB: ACCP), has signed an exclusive, ... for the development and commercialization of its proprietary ... new corporate management team and its intention to ... Biopharmaceuticals, Inc.™, and its plans to pursue a ...
(Date:9/22/2014)... Sept. 22, 2014 Research and Markets ... Chinese Diclofenac Industry Report 2014" report to their ... Industry Report 2014 is a professional and in-depth study ... with a focus on the Chinese situation. ... including definitions, classifications, applications and industry chain structure. The ...
(Date:9/20/2014)... 20, 2014 /CNW/ - The issue: Mylan Pharmaceuticals ULC Canada, ... of its Mylan-Nitro Spray 0.4 mg/metered dose due to the ... pump component. A missing "dip tube" could ... the patient. This defect may lead patients to believe they ... to access it. Not receiving nitroglycerin could place them at ...
Breaking Medicine Technology:Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 2Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 4Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 5Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 6Global and Chinese Diclofenac Industry Report 2014 2Advisory - Mylan Pharmaceuticals recalling nitroglycerin spray due to defective pump 2
... November 2005. Specifications, including colors, subject to ... lb (2.3 kg), FreeStyle by AirSep is ... for those patients who know no boundaries. ... FreeStyle captures the heart of what it ...
... is AirSep Corporations most economical line of ... lpm of therapeutic oxygen in home, hospital, ... of units in daily use throughout the ... known for high performance, easy maintenance, and ...
... to 10 LPM of oxygen reducing the delivery ... M10 is engineered to reduce the cost of ... fewer parts than any other concentrator on the ... you to reduce expenditure on accessories and unnecessary ...
... conserver, it's important to have a choice that ... name synonymous with innovative excellence, offers two great ... automatic and value packed conservers., ,With its ... used 8 hours a day for 3 to ...
Medicine Products: